How will the FDA approval of Ohtuvayre impact Structure Therapeutics' stock price?

The FDA approval of Ohtuvayre is unlikely to have a direct impact on Structure Therapeutics' stock price, primarily because the approval is not a result of Structure's efforts or financial benefits from the drug's sales. Here's why:

1. **No Financial Benefit**: Structure does not receive any financial benefit from the FDA approval of Ohtuvayre, as it is not a direct beneficiary of the approval. The approval is a result of Ligand Pharmaceuticals' partnership with Verona Pharma, not Structure Therapeutics.
2. **No Earnings Impact**: There is no immediate earnings impact on Structure, as it does not receive any revenue share from Ohtuvayre's sales.
3. **Investor Sentiment**: The approval could positively influence investor sentiment towards Ligand and Verona Pharma, potentially driving their stock prices higher. However, this may not directly affect Structure's stock price unless there is a broader market sentiment shift.
4. **Future Developments**: Future developments, such as potential partnerships or licensing deals related to Ohtuvayre, could indirectly benefit Structure if it were to participate in those arrangements. However, this is speculative and not a guarantee of financial or stock price impact.

In conclusion, while the FDA approval of Ohtuvayre is a positive development, it is not expected to have a direct impact on Structure Therapeutics' stock price due to the lack of financial benefit or immediate earnings impact. Any potential influence on the stock price would be more indirect, tied to broader market sentiment or future developments.